AA
ANRO icon

ALPS Advisors’s Alto Neuroscience ANRO Stock Holding History

ALPS Advisors’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$568K Sell
25,288
-217
-0.9% -$4.02K ﹤0.01% 678
2025
Q4 		$454K Buy
+25,505
New +$321K ﹤0.01% 807
2024
Q4 		– Sell
-21,309
Closed -$244K – 1044
2024
Q3 		$244K Buy
21,309
+328
+2% +$4.01K ﹤0.01% 971
2024
Q2 		$224K Buy
+20,981
New +$273K ﹤0.01% 945

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ALPS Advisors's ANRO Position: Q1 2026 in Review

ALPS Advisors reduced its Alto Neuroscience (ANRO) stake by 0.85% in Q1 2026, selling an estimated $4.02K and leaving 25,288 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #678.

ALPS Advisors first reported a position in ANRO in Q2 2024 and has held it in 4 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • ALPS Advisors held 25,288 shares of Alto Neuroscience worth $568K as of Q1 2026.
  • ALPS Advisors sold 217 Alto Neuroscience shares in Q1 2026, an estimated $4.02K.
  • Alto Neuroscience made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #678 holding.
  • ALPS Advisors first reported a position in Alto Neuroscience in Q2 2024 and has held it in 4 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.